Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TKPHF) Net Margin (2017 - 2025)

Historic Net Margin for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to 8.7%.

  • Takeda Pharmaceutical's Net Margin fell 20700.0% to 8.7% in Q4 2025 from the same period last year, while for Dec 2025 it was 18.22%, marking a year-over-year increase of 49700.0%. This contributed to the annual value of 2.36% for FY2025, which is 10200.0% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Net Margin of 8.7% as of Q4 2025, which was down 20700.0% from 19.81% recorded in Q3 2025.
  • Takeda Pharmaceutical's Net Margin's 5-year high stood at 25.59% during Q1 2021, with a 5-year trough of 1.17% in Q1 2022.
  • For the 5-year period, Takeda Pharmaceutical's Net Margin averaged around 12.77%, with its median value being 10.83% (2022).
  • In the last 5 years, Takeda Pharmaceutical's Net Margin surged by 253800bps in 2021 and then crashed by -267600bps in 2022.
  • Takeda Pharmaceutical's Net Margin (Quarter) stood at 6.41% in 2021, then surged by 69bps to 10.86% in 2022, then skyrocketed by 39bps to 15.15% in 2023, then decreased by -29bps to 10.76% in 2024, then decreased by -19bps to 8.7% in 2025.
  • Its Net Margin stands at 8.7% for Q4 2025, versus 19.81% for Q3 2025 and 18.05% for Q2 2025.